ReviewBrain tumor pathology2025
Primary pigmented papillary epithelial tumor of the sella: case report and literature review.
Review in Brain tumor pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pigmented papillary epithelial tumor of the sella (PPPET) is a recently identified tumor entity that commonly originates in the sella. To date, only three cases have been documented. These tumors are characterized by a papillary structure and significant melanin granule deposition. Notably, molecular characterization of PPPET remains unreported in the literature. A 42-year-old male presented with left-sided visual impairment for 2 weeks. Neuroimaging revealed a round sellar hyperdense mass. Histologically, the tumor exhibited minimal nuclear atypia and was characterized by a papillary architecture and obvious intracellular hyperpigmentation. Immunophenotypically, tumor cells showed diffuse positivity for S-100 and Melan-A, partial or focal positivity for synaptophysin and CD56, and negativity for TTF-1, GFAP, EMA, cytokeratins, and pituitary hormones. The Ki-67 proliferation index was low. The whole exome sequencing (WES) analysis revealed multiple potentially pathogenic gene mutations (AGAP3, DDX10, BBX, NFATC4, SLC6A6) in tumor tissues. Large genomic rearrangements (LGRs) involving PRKRA (exon6-8 del) and SKA3 (exon2-8 del) were detected. Genomic instability analysis indicated whole genome doubling (WGD) and aneuploidy in the tumor cells. Copy number variation (CNV) analysis demonstrated extensive copy number abnormalities at the chromosome arm level in tumor tissues. No classical mutations associated with known tumor types of the sella and choroid plexus were detected. PPPET has unique morphologic, immunohistochemical, and molecular genetic characteristics. Our findings suggest that PPPET may be an independent neurooncological entity.
Indexed as
Identifiers
40616715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.